news
11 February 2020
Da Volterra Announces Positive Top-line Results from a Phase 2 Clinical Trial Evaluating DAV132 in 260 Patients
• First clinical study evaluating DAV132 in patients • Primary endpoint met: DAV132 was safe for use in…
Da Volterra is pleased to be a sponsor of the 6th International C. difficile Symposium taking place September 12-14th, 2018 in Bled Slovenia. The conference is certain to be highly stimulating with an impressive program and speaker list! More information may be found on the website.